John Jones
University of Nottingham
Publications 14
#1Clare T. Atherton (University of Nottingham)H-Index: 5
#2John Jones (University of Nottingham)H-Index: 4
Last.Christopher J. Hawkey (University of Nottingham)H-Index: 79
view all 13 authors...
Abstract Background & Aims: Lumiracoxib is a structurally novel, acidic selective inhibitor of cyclooxygenase (COX)-2. We coordinated existing methodologies in a single study to evaluate potency, selectivity, and effect on the human gastrointestinal tract. Methods: Twenty four healthy subjects (aged 18–45 years, 12 female) received high dose lumiracoxib (800 mg every day), standard dose naproxen (500 mg twice a day), or placebo for 8 days in a double-blind randomized crossover study. At the star...
38 CitationsSource
#1Bror Jonzon (AstraZeneca)H-Index: 7
#2Ingvar BjarnasonH-Index: 58
Last.Pär Karlsson (AstraZeneca)H-Index: 7
view all 7 authors...
COX-inhibiting nitric oxide donators (CINODs) are a new class of drugs in development for the treatment of acute and chronic pain. They comprise a COX-inhibiting moiety linked to a nitric-oxide-donating component and are designed to provide an innovative mechanism of action of balanced COX inhibition and controlled nitric oxide donation. Through these pathways, CINODs should provide analgesic and anti-inflammatory efficacy, while offering gastrointestinal safety through the tissue-protective eff...
9 CitationsSource
#2John JonesH-Index: 4
Last.I T BjarnasonH-Index: 1
view all 9 authors...
Background: Cyclooxygenase inhibiting nitric oxide donators (CINODs) are a new class of anti-inflammatory and analgesic drugs that may minimise gastrointestinal toxicity compared with standard non-steroidal anti-inflammatory drugs (NSAIDs) by virtue of nitric oxide donation. Methods: A proof of concept study of the gastrointestinal safety of AZD3582, the first CINOD available for human testing, was conducted. Thirty one subjects were randomised to receive placebo, naproxen 500 mg twice daily, or...
90 CitationsSource
#1John JonesH-Index: 4
Last.Christopher J. HawkeyH-Index: 79
view all 4 authors...
#1Clare T. AthertonH-Index: 5
Last.Christopher J. HawkeyH-Index: 79
view all 11 authors...
#1Ingvar Bjarnason ('KCL': King's College London)H-Index: 58
Last.Pär KarlssonH-Index: 7
view all 7 authors...
#1John Jones (University of Nottingham)H-Index: 4
#2Christopher J. Hawkey (University of Nottingham)H-Index: 79
Abstract Peptic ulcer disease, particularly as a result of its complications, is a burden that is focused on the elderly through their higher Helicobacter pylori prevalence and use of non-steroidal anti-inflammatory drugs (NSAIDs). In these patients, senescence may further increase ulcer susceptibility, particularly in the stomach, by the loss of mucosal protection and repair mechanisms. Age is mainly a marker for the increased prevalence of other complicated ulcer risk factors such as previous ...
16 CitationsSource
#1John JonesH-Index: 4
#2Joanne L. BroughH-Index: 5
Last.Christopher J. HawkeyH-Index: 79
view all 5 authors...